Article
KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance).
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jun 2014
Yoon Harry H, Tougeron David, Shi Qian, Alberts Steven R, Mahoney Michelle R, Nelson Garth D, Nair Suresh G, Thibodeau Stephen N, Goldberg Richard M, Sargent Daniel J, Sinicrope Frank A
Abstract excerpt
PURPOSE: We examined the prognostic impact of specific KRAS mutations in patients with stage III colon adenocarcinoma receiving adjuvant FOLFOX alone or combined with cetuximab in a phase III trial (N0147). Analysis was restricted to BRAF-wild-type tumors, because BRAF mutation was associated with poor prognosis, and BRAF and KRAS mutations are mutually exclusive. EXPERIMENTAL DESIGN: The seven most common KRAS...
Topics
- Adenocarcinoma
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols
- Cetuximab
- Chemotherapy, Adjuvant
- Codon